
Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
I'm a hypnotherapist who helps day traders who are losing money. Here's why I think hypnosis works. - 2
Vote in favor of your Number one Kind of Shades - 3
‘We are the alternative’: Anti-Hamas Gaza militia tells BBC group is receiving international support - 4
'We need everyone,' wounded reservist urges Knesset panel to advance haredi draft law - 5
'Dancing With the Stars' Season 34 finale: Who might win the mirror ball trophy? Where do the remaining contestants rank?
5 Morning Schedules That Stimulate Your Day
Kona SUV: The Courageous Minimized That is Catching Hearts Around the world
Iconic iceberg turns blue, on verge of totally disintegrating, NASA says
NASA launches science balloon in Antarctica | Space photo of the day for Dec. 22, 2025
Blue Origin's next space tourism flight will break new ground for people with disabilities
Sean 'Diddy' Combs faces new sexual assault allegations, currently under investigation by Los Angeles Sheriff's Department
The Delight of Perusing: Book Proposals for Each Class
Most loved VR Game for Wellness: Which Keeps You Dynamic?
Putin says Russian forces will seize capital of Zaporizhzhya












